ALDVI — Advicenne SA Share News
0.000.00%
Last trade - 00:00- €15.83m
- €33.49m
- €6.01m
Corrected: BRIEF-Advicenne FY Net Income EUR -9.532 Million (March 26)
France's Advicenne 2025 sales rise, net loss widens
Brief: Advicenne FY Net Income EUR -9.532 Million
Brief: Advicenne SA -Cash Position Of EUR 2.0 Million With Unchanged Financial Visibility In Q1 2025
Brief: Advicenne Eyes Operational Profitability During Q4
Brief: Advicenne FY EPS EUR -0.67
Brief: Advicenne: FDA Grants Orphan Drug Designation To ADV7103 For Treatment Of Cystinuria
Brief: Advicenne FY Gross Sales Up 20% At EUR 4.43 Mln
Brief: Advicenne H1 Consolidated Net Loss Narrows To EUR 3.73 Million
Brief: Advicenne FY Net Loss Narrows To EUR 11.5 Mln
Brief: Advicenne Announces The Launch Of Sibnayal In Denmark
Brief: Advicenne Signs Sibnayal Distribution Agreement With Avanzanite Bioscience
Brief: Advicenne Partners With SPA For Distribution Of Sibnayal In Italy, Spain, Portugal
Brief: Advicenne FY Sales Up At €3.7 Million
Brief: Advicenne's ADV7103 Gets ODD For Distal Renal Tubular Acidosis
Brief: Advicenne: Extension Of Sibnayal Patents
Brief: Advicenne H1 Net Loss Narrows To EUR 4.8 Mln
Brief: Advicenne's Sibnayal® Accepted For Use Within NHS Scotland
Brief: Advicenne Announces Commercial Launch Of Sibnayal In Great Britain